For pancreatic tumors, several ancillary IHC markers are used in this setting, with the loss of Rb and aberrant p53 (block positive or completely lost) supporting NEC, while the loss of DAXX and ATRX supporting NET20,26. The gene discussed is RB1; the disease is neuroendocrine carcinoma.